DIVESTITURES	6 Months Ended
Jun. 27, 2026
Discontinued Operations and Disposal Groups [Abstract]
DIVESTITURES	DIVESTITURES Divestitures During the Three Months Ended June 27, 2026 Dermacosmetics Business On April 30, 2026, the sale of the Dermacosmetics Business was completed for total consideration of $362.9 million, net of cash delivered. The transaction consists of €305.6 million, or $358.5 million, in upfront cash, $6.2 million of proceeds received for inventory on hand, less $1.8 million of cash delivered. The transaction also stipulates up to an additional €27.0 million contingent on the achievement of net sales milestones, of which €18.0 million is remaining through 2027. The sale resulted in a pre-tax gain of $129.5 million recorded in Other (income) expense, net on the Consolidated Statements of Operations. Brands sold in the transaction include ACO, Biodermal, and Iwostin. The assets associated with this business were not included in any of our reporting segments and therefore were reported in All Other. The estimated fair value less costs to sell of the Dermacosmetics Business exceeded its carrying value. As such, no impairment charge was recorded during the year ended December 31, 2025 or the six months ended June 27, 2026. Divestitures During the Three Months Ended June 28, 2025 Richard Bittner Business On April 11, 2025, we completed the sale of the Richard Bittner Business AG, an Austrian contract manufacturing entity (the "Richard Bittner Business") to HBI Health & Beauty Innovations Limited for total consideration of $14.4 million, net of cash delivered. The sale resulted in a pre-tax loss of $1.6 million, net of professional fees, recorded in Other (income) expense, net on the Condensed Consolidated Statements of Operations within our Self Care segment. The assets associated with this business were reported within our Self Care segment. We determined the carrying value of the net assets held for sale of this business exceeded their fair value less costs to sell, resulting in a total impairment charge of $3.1 million during the six months ended June 28, 2025, inclusive of a goodwill impairment charge of $1.2 million.DISCONTINUED OPERATIONS Our discontinued operations primarily consist of our former Rx segment, which held our prescription pharmaceuticals business in the U.S. and our pharmaceuticals and diagnostic businesses in Israel (collectively, the “Rx business”). In connection with the sale of the Rx business, Perrigo retained certain pre-closing liabilities arising out of antitrust (refer to Note 16 under the header “Price-Fixing Lawsuits”) and opioid matters and the Company’s Albuterol recall, subject to, in each case, Altaris Capital Partners, LLC (“Altaris”) obligation to indemnify the Company for fifty percent of these liabilities up to an aggregate cap on Altaris' obligation of $50.0 million. As of June 27, 2026, the loss accrual for litigation contingencies reflected on the Condensed Consolidated Balance Sheets in Other accrued liabilities included $67.0 million related to price-fixing lawsuits. A recovery receivable was recorded for fifty percent of this liability as of June 27, 2026 reflected on the Condensed Consolidated Balance Sheets in Prepaid expenses and other current assets. Current and prior period reported net loss from discontinued operations primarily relates to the provision for litigation contingencies.

DIVESTITURES

6 Months Ended

Jun. 27, 2026

Discontinued Operations and Disposal Groups [Abstract]

Divestitures During the Three Months Ended June 27, 2026

Dermacosmetics Business

On April 30, 2026, the sale of the Dermacosmetics Business was completed for total consideration of $362.9 million, net of cash delivered. The transaction consists of €305.6 million, or $358.5 million, in upfront cash, $6.2 million of proceeds received for inventory on hand, less $1.8 million of cash delivered. The transaction also stipulates up to an additional €27.0 million contingent on the achievement of net sales milestones, of which €18.0 million is remaining through 2027. The sale resulted in a pre-tax gain of $129.5 million recorded in Other (income) expense, net on the Consolidated Statements of Operations. Brands sold in the transaction include ACO, Biodermal, and Iwostin.

The assets associated with this business were not included in any of our reporting segments and therefore were reported in All Other. The estimated fair value less costs to sell of the Dermacosmetics Business exceeded its carrying value. As such, no impairment charge was recorded during the year ended December 31, 2025 or the six months ended June 27, 2026.

Divestitures During the Three Months Ended June 28, 2025

Richard Bittner Business

On April 11, 2025, we completed the sale of the Richard Bittner Business AG, an Austrian contract manufacturing entity (the "Richard Bittner Business") to HBI Health & Beauty Innovations Limited for total consideration of $14.4 million, net of cash delivered. The sale resulted in a pre-tax loss of $1.6 million, net of professional fees, recorded in Other (income) expense, net on the Condensed Consolidated Statements of Operations within our Self Care segment.

The assets associated with this business were reported within our Self Care segment. We determined the carrying value of the net assets held for sale of this business exceeded their fair value less costs to sell, resulting in a total impairment charge of $3.1 million during the six months ended June 28, 2025, inclusive of a goodwill impairment charge of $1.2 million.DISCONTINUED OPERATIONS

Our discontinued operations primarily consist of our former Rx segment, which held our prescription pharmaceuticals business in the U.S. and our pharmaceuticals and diagnostic businesses in Israel (collectively, the “Rx business”).

In connection with the sale of the Rx business, Perrigo retained certain pre-closing liabilities arising out of antitrust (refer to Note 16 under the header “Price-Fixing Lawsuits”) and opioid matters and the Company’s Albuterol recall, subject to, in each case, Altaris Capital Partners, LLC (“Altaris”) obligation to indemnify the Company for fifty percent of these liabilities up to an aggregate cap on Altaris' obligation of $50.0 million. As of June 27, 2026, the loss accrual for litigation contingencies reflected on the Condensed Consolidated Balance Sheets in Other accrued liabilities included $67.0 million related to price-fixing lawsuits. A recovery receivable was recorded for fifty percent of this liability as of June 27, 2026 reflected on the Condensed Consolidated Balance Sheets in Prepaid expenses and other current assets.

Current and prior period reported net loss from discontinued operations primarily relates to the provision for litigation contingencies.